论文部分内容阅读
目的:分析头孢哌酮钠/舒巴坦钠治疗老年肺内感染的临床疗效及安全性。方法:选取我院在2012年1月~2014年12月期间收治的老年肺内感染患者100例,将其随机分成实验组和对照组,实验组患者接受头孢哌酮钠/舒巴坦钠治疗,对照组患者接受头孢哌酮钠治疗,比较实验组患者和对照组患者的临床效果、痰菌清除率以及不良反应发生情况。结果:实验组患者的总有效率为94.00%,明显高于对照组患者的总有效率88.00%,差异具有统计学意义(P<0.05);实验组患者的痰菌清除率为88.00%,明显高于对照组患者的痰菌清除率80.00%,差异具有统计学意义(P<0.05);实验组患者的不良反应发生率为6.00%,对照组患者的不良反应发生率为4.00%,实验组患者和对照组患者的不良反应发生率无明显差异,不具有统计学意义(P>0.05)。结论:头孢哌酮钠/舒巴坦钠治疗老年肺内感染的总有效率高,不良反应发生率较低,疗效显著,安全性高,值得临床大力推广应用。
Objective: To analyze the clinical efficacy and safety of cefoperazone sodium / sulbactam sodium in the treatment of elderly pulmonary infection. Methods: A total of 100 elderly patients with pulmonary infection were selected from January 2012 to December 2014 in our hospital. The patients were randomly divided into experimental group and control group. Patients in experimental group received cefoperazone sodium / sulbactam sodium, while those in control group Patients received cefoperazone sodium treatment, the clinical efficacy of the patients in the experimental group and the control group, the sputum clearance rate and adverse reactions. Results: The total effective rate of the experimental group was 94.00%, which was significantly higher than that of the control group (88.00%), the difference was statistically significant (P <0.05). The sputum bacterial clearance rate was 88.00% in the experimental group The sputum bacterial clearance rate was 80.00% higher than that of the control group (P <0.05). The incidence of adverse reactions in the experimental group was 6.00%, the incidence of adverse reactions in the control group was 4.00% There was no significant difference in the incidence of adverse reactions between patients and controls (P> 0.05). CONCLUSION: Cefoperazone sodium / sulbactam sodium is effective in treating elderly pulmonary infection with low incidence of adverse reactions, significant curative effect and high safety. It is worth popularizing and applying clinically.